Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Male mucinous adenocarcinoma of the urethra (MAU) is rare and lacks any standard options for systemic therapy. Genomic analysis of this rare tumor has demonstrated a targetable amplification of epidermal growth factor receptor (EGFR). Erlotinib is effective in EGFR-amplified MAU. Follow-up immunohistochemistry in this case and 6 other archival cases demonstrate that EGFR overexpression is a recurrent abnormality. These findings have identified a new biomarker, EGFR, which can be tested for in future MAU cases to inform treatment decisions. (C) 2016 The Authors. Published by Elsevier Inc.